Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions DOI Creative Commons

Sushanth Sreenivasan,

Rahim Jiwani, Richard White

et al.

Current Oncology, Journal Year: 2025, Volume and Issue: 32(4), P. 232 - 232

Published: April 16, 2025

Salivary gland carcinomas (SGCs) represent a rare and heterogeneous group of malignancies accounting for 3–6% all head neck cancers. While surgical resection radiotherapy remain the standard locoregional control, systemic treatment is indicated recurrent or metastatic disease. Advances in molecular profiling have identified actionable targets such as NTRK gene fusions, HER2, immune checkpoint regulators, androgen receptors, RET receptors. These facilitated development targeted therapies, including TRK inhibitors, HER2-directed agents, receptor modulators, well emerging combinations immunotherapy chemotherapy. Despite these advancements, challenges resistance mechanisms limited therapeutic efficacy persist. Overall response rates relatively low across most reflecting persistent unmet clinical need. This review discusses current landscape options explores promising trials future directions to enhance outcomes patients with SGCs.

Language: Английский

Cystine-Modified Lignin–Copper Coordination Nanocarriers Improve the Therapeutic Efficacy of Tyrosine Kinase Inhibition via Cuproptosis DOI

Shiyao Song,

Xingfeng Qiu,

Shaoqing Huang

et al.

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

The clinical application of tyrosine kinase inhibitors (TKIs) is rapidly growing and has emerged as a cornerstone in the treatment both solid tumors hematologic malignancies. However, resistance to TKI targets disease progression remain inevitable. Nanocarrier-mediated delivery promising strategy overcome limitations application. We utilized facile modification lignin polyhydroxyl groups synthesize cystine-grafted lignin–copper coordinated nanoparticles for via Mannich reaction. materials exhibited stable, uniform morphology effectively encapsulated delivered variety inhibitors. Moreover, we optimized fabrication process found that material could release drug response pH GSH. These significantly enhanced therapeutic activity TKIs vitro vivo through cuproptosis while demonstrating good biosafety. propose novel targeted by combining with modified lignin. This approach not only offers new strategies but also provides insights inspiration use

Language: Английский

Citations

0
Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research DOI Open Access

Nauf Bou Antoun,

Hiba-Tun-Noor A. Mahmood,

Anthony J. Walker

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 1799 - 1799

Published: Feb. 20, 2025

Primary or acquired resistance to therapeutic agents is a major obstacle in the treatment of cancer patients. Cervical fourth leading cause deaths among women worldwide and, despite advances screening and treatments, many patients with advanced stage cervical have high recurrence rate within two years standard treatment, drug being contributing factor. The development cell lines can facilitate comprehensive investigation mechanisms, which cannot be easily performed clinical trials. This study aimed create three novel robust (HeLa, CaSki, SiHa) fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor (PD173074). All drug-resistant (DR) overexpressed FGFR1, FGFR2, FGF2, FGF4, FGF7 proteins that were also localized nucleus. In addition, DR cells had significantly more aggressive phenotype (more migratory proliferative, less apoptotic) compared parental lines. These are critical tool for understanding molecular mechanisms underpinning identification potential biomarkers. Moreover, availability such may effective strategies using FGFR inhibitors combination other target pathways responsible inhibitors.

Language: Английский

Citations

0
Immunomodulation on tumor immune microenvironment in acquired targeted therapy resistance and implication for immunotherapy resistance DOI

Ming-Yu Chou,

Muh‐Hwa Yang

Translational Oncology, Journal Year: 2025, Volume and Issue: 54, P. 102353 - 102353

Published: March 8, 2025

Language: Английский

Citations

0
Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions DOI Creative Commons

Sushanth Sreenivasan,

Rahim Jiwani, Richard White

et al.

Current Oncology, Journal Year: 2025, Volume and Issue: 32(4), P. 232 - 232

Published: April 16, 2025

Salivary gland carcinomas (SGCs) represent a rare and heterogeneous group of malignancies accounting for 3–6% all head neck cancers. While surgical resection radiotherapy remain the standard locoregional control, systemic treatment is indicated recurrent or metastatic disease. Advances in molecular profiling have identified actionable targets such as NTRK gene fusions, HER2, immune checkpoint regulators, androgen receptors, RET receptors. These facilitated development targeted therapies, including TRK inhibitors, HER2-directed agents, receptor modulators, well emerging combinations immunotherapy chemotherapy. Despite these advancements, challenges resistance mechanisms limited therapeutic efficacy persist. Overall response rates relatively low across most reflecting persistent unmet clinical need. This review discusses current landscape options explores promising trials future directions to enhance outcomes patients with SGCs.

Language: Английский

Citations

0